On December 26th 2023, AbbVie announced that it will acquire Massachusetts based biotech Cerevel Therapeutics for $45.00 per share. The transaction represents an equity value
AbbVie has agreed to acquire cancer biotech ImmunoGen (IMGN) for $10.1 billion in an all cash offering for $31.26 per share. J.P Morgan and Morgan
Suppose you were teleported to Copenhagen, Denmark this instant. A look around would yield a scene far different from what we are accustomed to in
For an estimated 6.7 million Americans, the days are the same. Memory loss, poor judgment, difficulty completing simple tasks, and getting lost are a few
When you think of NAPA your mind might conjure up tasting great wine or touring through the beautiful countryside north of San Francisco. However, the
In what has been a down year for mergers and acquisitions deals, Amgen made headlines late last year by announcing it will acquire Horizon for